Drug Profile
PF 4991532
Alternative Names: PF-04991532; PF-4991532Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 May 2012 Pfizer completes a phase I trial in Type-2 diabetes mellitus in USA and Japan (NCT01469065)
- 22 May 2012 Pfizer completes enrolment in a phase I trial in Type-2 diabetes mellitus in USA and Japan (NCT01469065)
- 10 May 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO)